首页> 外文期刊>Endocrine journal >Ratio of Serum Free Triiodothyronine to Free Thyroxine in Graves' Hyperthyroidism and Thyrotoxicosis Caused by Painless Thyroiditis
【24h】

Ratio of Serum Free Triiodothyronine to Free Thyroxine in Graves' Hyperthyroidism and Thyrotoxicosis Caused by Painless Thyroiditis

机译:无痛性甲状腺炎引起的格雷夫斯甲状腺功能亢进症和甲状腺毒症中血清游离三碘甲状腺素与游离甲状腺素的比值

获取原文
           

摘要

References(18) Cited-By(11) The serum T3 to T4 ratio is a useful indicator for differentiating destruction-induced thyrotoxicosis from Graves' thyrotoxicosis. However, the usefulness of the serum free T3 (FT 3) to free T4 (FT4) ratio is controversial. We therefore systematically evaluated the usefulness of this ratio, based on measurements made using two widely available commercial kits in two hospitals. Eighty-two untreated patients with thyrotoxicosis (48 patients with Graves' disease and 34 patients with painless thyroiditis) were examined in Kuma Hospital, and 218 patients (126 with Graves' disease and 92 with painless thyroiditis) and 66 normal controls were examined in Ito Hospital. The FT3 and FT4 values, as well as the FT3/FT4 ratios, were significantly higher in the patients with Graves' disease than in those with painless thyroiditis in both hospitals, but considerable overlap between the two disorders was observed. Receiver operating characteristic (ROC) curves for the FT3 and FT4 values and the FT3/FT4 ratios of patients with Graves' disease and those with painless thyroiditis seen in both hospitals were prepared, and the area under the curves (AUC), the cut-off points for discriminating Graves' disease from painless thyroiditis, the sensitivity, and the specificity were calculated. AUC and sensitivity of the FT3/FT4 ratio were smaller than those of FT3 and FT4 in both hospitals. The patients treated at Ito hospital were then divided into 4 groups according to their FT4 levels (A: ≤2.3, B: >2.3~≤3.9, C: 3.9~≤5.4, D: >5.4 ng/dl), and the AUC, cut-off points, sensitivity, and specificity of the FT3/FT4 ratios were calculated. The AUC and sensitivity of each group increased with the FT4 levels (AUC: 57.8%, 72.1%, 91.1%, and 93.4%, respectively; sensitivity: 62.6%, 50.0%, 77.8%, and 97.0%, respectively). The means ± SE of the FT3/FT4 ratio in the Graves' disease groups were 3.1 ± 0.22, 3.1 ± 0.09, 3.2 ± 0.06, and 3.1 ± 0.07, respectively, versus 2.9 ± 0.1, 2.6 ± 0.07, 2.5 ± 0.12, and 2.3 ± 0.15, respectively, in the painless thyroiditis groups. In the painless thyroiditis patients, the difference in the FT3/FT4 ratio between group A and group D was significant (p<0.05). Thus, the FT3/FT4 ratio in patients with Graves' disease likely remains unchanged as the FT4 level rises, whereas this ratio decreases as the FT4 level rises in patients with painless thyroiditis. In conclusion, the FT3/FT 4 ratios of patients with painless thyroiditis overlapped with those of patients with Graves' disease. However, this ratio was useful for differentiating between these two disorders when the FT4 values were high.
机译:参考文献(18)引用(11)血清T3与T4的比率是区分破坏引起的甲状腺毒症和Graves甲状腺毒症的有用指标。但是,血清游离T3(FT 3)与游离T4(FT4)之比的有用性存在争议。因此,我们基于在两家医院使用两种广泛使用的商业套件进行的测量,系统地评估了该比率的有效性。在库玛医院检查了82例未经治疗的甲状腺毒症患者(48例Graves病患者和34例无痛性甲状腺炎患者),对218例患者(126例Graves病和92例无痛性甲状腺炎)和66例正常对照者进行了伊藤检查医院。在两家医院中,格雷夫斯病患者的FT3和FT4值以及FT3 / FT4比率均显着高于无痛性甲状腺炎患者,但观察到这两种疾病之间存在相当大的重叠。绘制了两家医院的Graves病患者和无痛性甲状腺炎患者的FT3和FT4值以及FT3 / FT4比的接收器工作特征(ROC)曲线,并绘制了曲线下面积(AUC),计算区分格雷夫斯病和无痛性甲状腺炎的起点,敏感性和特异性。两家医院的FT3 / FT4比值的AUC和敏感性均小于FT3和FT4。然后根据伊藤医院的FT4水平将患者分为4组(A:≤2.3,B:> 2.3〜≤3.9,C:3.9〜≤5.4,D:> 5.4 ng / dl),以及AUC ,计算了FT3 / FT4比值的临界点,敏感性和特异性。每组的AUC和敏感性均随FT4水平的升高而增加(AUC分别为57.8%,72.1%,91.1%和93.4%;敏感性:分别为62.6%,50.0%,77.8%和97.0%)。格雷夫斯病组中FT3 / FT4比率的平均值±SE分别为3.1±0.22、3.1±0.09、3.2±0.06和3.1±0.07,而2.9±0.1、2.6±0.07、2.5±0.12和无痛性甲状腺炎组分别为2.3±0.15。在无痛性甲状腺炎患者中,A组和D组之间的FT3 / FT4比值差异显着(p <0.05)。因此,格雷夫斯病患者的FT3 / FT4比值可能会随着FT4水平的升高而保持不变,而该比例随着无痛性甲状腺炎患者中FT4水平的升高而降低。总之,无痛性甲状腺炎患者的FT3 / FT 4比值与Graves病患者的FT3 / FT 4比值重叠。但是,当FT4值较高时,该比率可用于区分这两种疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号